CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies

Brigitte C. Widemann, Maria T. Acosta, Sylvia Ammoun, Allan J. Belzberg, Andre Bernards, Jaishri Blakeley, Antony Bretscher, Karen Cichowski, D. Clapp, Eva Dombi, Gareth D. Evans, Rosalie Ferner, Cristina Fernandez-Valle, Michael J. Fisher, Marco Giovannini, David H. Gutmann, C. Oliver Hanemann, Robert Hennigan, Susan Huson, David IngramJoe Kissil, Bruce R. Korf, Eric Legius, Roger J. Packer, Andrea I. Mcclatchey, Frank Mccormick, Kathryn North, Minja Pehrsson, Scott R. Plotkin, Vijaya Ramesh, Nancy Ratner, Susann Schirmer, Larry Sherman, Elizabeth Schorry, David Stevenson, Douglas R. Stewart, Nicole Ullrich, Annette C. Bakker, Helen Morrison

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The neurofibromatoses (NF) are autosomal dominant genetic disorders that encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect more people worldwide than Duchenne muscular dystrophy and Huntington's disease combined. NF1 and NF2 are caused by mutations of known tumor suppressor genes (NF1 and NF2, respectively). For schwannomatosis, although mutations in SMARCB1 were identified in a subpopulation of schwannomatosis patients, additional causative gene mutations are still to be discovered. Individuals with NF1 may demonstrate manifestations in multiple organ systems, including tumors of the nervous system, learning disabilities, and physical disfigurement. NF2 ultimately can cause deafness, cranial nerve deficits, and additional severe morbidities caused by tumors of the nervous system. Unmanageable pain is a key finding in patients with schwannomatosis. Although today there is no marketed treatment for NF-related tumors, a significant number of clinical trials have become available. In addition, significant preclinical efforts have led to a more rational selection of potential drug candidates for NF trials. An important element in fueling this progress is the sharing of knowledge. For over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share novel findings, ideas, and build collaborations. The 2012 NF Conference held in New Orleans hosted over 350 NF researchers and clinicians. This article provides a synthesis of the highlights presented at the conference and as such, is a "state-of-the-field" for NF research in 2012.

Original languageEnglish
Pages (from-to)563-578
Number of pages16
JournalAmerican Journal of Medical Genetics, Part A
Volume164
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Neurofibromatoses
Nervous System Neoplasms
Therapeutics
Mutation
Inborn Genetic Diseases
Duchenne Muscular Dystrophy
Schwannomatosis
Cranial Nerves
Learning Disorders
Huntington Disease
Deafness
Muscular Diseases
Rare Diseases
Tumor Suppressor Genes
Neoplasms
Research Personnel
Clinical Trials
Morbidity
Pain
Research

Keywords

  • Merlin neurofibromin
  • Neurofibromatosis type 1
  • Neurofibromatosis type 2
  • NF1
  • NF2
  • Preclinical models
  • Schwannomatosis
  • SMARCB1
  • Tumor suppressor

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

CTF meeting 2012 : Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. / Widemann, Brigitte C.; Acosta, Maria T.; Ammoun, Sylvia; Belzberg, Allan J.; Bernards, Andre; Blakeley, Jaishri; Bretscher, Antony; Cichowski, Karen; Clapp, D.; Dombi, Eva; Evans, Gareth D.; Ferner, Rosalie; Fernandez-Valle, Cristina; Fisher, Michael J.; Giovannini, Marco; Gutmann, David H.; Hanemann, C. Oliver; Hennigan, Robert; Huson, Susan; Ingram, David; Kissil, Joe; Korf, Bruce R.; Legius, Eric; Packer, Roger J.; Mcclatchey, Andrea I.; Mccormick, Frank; North, Kathryn; Pehrsson, Minja; Plotkin, Scott R.; Ramesh, Vijaya; Ratner, Nancy; Schirmer, Susann; Sherman, Larry; Schorry, Elizabeth; Stevenson, David; Stewart, Douglas R.; Ullrich, Nicole; Bakker, Annette C.; Morrison, Helen.

In: American Journal of Medical Genetics, Part A, Vol. 164, No. 3, 03.2014, p. 563-578.

Research output: Contribution to journalArticle

Widemann, BC, Acosta, MT, Ammoun, S, Belzberg, AJ, Bernards, A, Blakeley, J, Bretscher, A, Cichowski, K, Clapp, D, Dombi, E, Evans, GD, Ferner, R, Fernandez-Valle, C, Fisher, MJ, Giovannini, M, Gutmann, DH, Hanemann, CO, Hennigan, R, Huson, S, Ingram, D, Kissil, J, Korf, BR, Legius, E, Packer, RJ, Mcclatchey, AI, Mccormick, F, North, K, Pehrsson, M, Plotkin, SR, Ramesh, V, Ratner, N, Schirmer, S, Sherman, L, Schorry, E, Stevenson, D, Stewart, DR, Ullrich, N, Bakker, AC & Morrison, H 2014, 'CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies', American Journal of Medical Genetics, Part A, vol. 164, no. 3, pp. 563-578. https://doi.org/10.1002/ajmg.a.36312
Widemann, Brigitte C. ; Acosta, Maria T. ; Ammoun, Sylvia ; Belzberg, Allan J. ; Bernards, Andre ; Blakeley, Jaishri ; Bretscher, Antony ; Cichowski, Karen ; Clapp, D. ; Dombi, Eva ; Evans, Gareth D. ; Ferner, Rosalie ; Fernandez-Valle, Cristina ; Fisher, Michael J. ; Giovannini, Marco ; Gutmann, David H. ; Hanemann, C. Oliver ; Hennigan, Robert ; Huson, Susan ; Ingram, David ; Kissil, Joe ; Korf, Bruce R. ; Legius, Eric ; Packer, Roger J. ; Mcclatchey, Andrea I. ; Mccormick, Frank ; North, Kathryn ; Pehrsson, Minja ; Plotkin, Scott R. ; Ramesh, Vijaya ; Ratner, Nancy ; Schirmer, Susann ; Sherman, Larry ; Schorry, Elizabeth ; Stevenson, David ; Stewart, Douglas R. ; Ullrich, Nicole ; Bakker, Annette C. ; Morrison, Helen. / CTF meeting 2012 : Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. In: American Journal of Medical Genetics, Part A. 2014 ; Vol. 164, No. 3. pp. 563-578.
@article{9455fbabe85c41e2b930c4e2a4c50487,
title = "CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies",
abstract = "The neurofibromatoses (NF) are autosomal dominant genetic disorders that encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect more people worldwide than Duchenne muscular dystrophy and Huntington's disease combined. NF1 and NF2 are caused by mutations of known tumor suppressor genes (NF1 and NF2, respectively). For schwannomatosis, although mutations in SMARCB1 were identified in a subpopulation of schwannomatosis patients, additional causative gene mutations are still to be discovered. Individuals with NF1 may demonstrate manifestations in multiple organ systems, including tumors of the nervous system, learning disabilities, and physical disfigurement. NF2 ultimately can cause deafness, cranial nerve deficits, and additional severe morbidities caused by tumors of the nervous system. Unmanageable pain is a key finding in patients with schwannomatosis. Although today there is no marketed treatment for NF-related tumors, a significant number of clinical trials have become available. In addition, significant preclinical efforts have led to a more rational selection of potential drug candidates for NF trials. An important element in fueling this progress is the sharing of knowledge. For over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share novel findings, ideas, and build collaborations. The 2012 NF Conference held in New Orleans hosted over 350 NF researchers and clinicians. This article provides a synthesis of the highlights presented at the conference and as such, is a {"}state-of-the-field{"} for NF research in 2012.",
keywords = "Merlin neurofibromin, Neurofibromatosis type 1, Neurofibromatosis type 2, NF1, NF2, Preclinical models, Schwannomatosis, SMARCB1, Tumor suppressor",
author = "Widemann, {Brigitte C.} and Acosta, {Maria T.} and Sylvia Ammoun and Belzberg, {Allan J.} and Andre Bernards and Jaishri Blakeley and Antony Bretscher and Karen Cichowski and D. Clapp and Eva Dombi and Evans, {Gareth D.} and Rosalie Ferner and Cristina Fernandez-Valle and Fisher, {Michael J.} and Marco Giovannini and Gutmann, {David H.} and Hanemann, {C. Oliver} and Robert Hennigan and Susan Huson and David Ingram and Joe Kissil and Korf, {Bruce R.} and Eric Legius and Packer, {Roger J.} and Mcclatchey, {Andrea I.} and Frank Mccormick and Kathryn North and Minja Pehrsson and Plotkin, {Scott R.} and Vijaya Ramesh and Nancy Ratner and Susann Schirmer and Larry Sherman and Elizabeth Schorry and David Stevenson and Stewart, {Douglas R.} and Nicole Ullrich and Bakker, {Annette C.} and Helen Morrison",
year = "2014",
month = "3",
doi = "10.1002/ajmg.a.36312",
language = "English",
volume = "164",
pages = "563--578",
journal = "American Journal of Medical Genetics, Part C: Seminars in Medical Genetics",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - CTF meeting 2012

T2 - Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies

AU - Widemann, Brigitte C.

AU - Acosta, Maria T.

AU - Ammoun, Sylvia

AU - Belzberg, Allan J.

AU - Bernards, Andre

AU - Blakeley, Jaishri

AU - Bretscher, Antony

AU - Cichowski, Karen

AU - Clapp, D.

AU - Dombi, Eva

AU - Evans, Gareth D.

AU - Ferner, Rosalie

AU - Fernandez-Valle, Cristina

AU - Fisher, Michael J.

AU - Giovannini, Marco

AU - Gutmann, David H.

AU - Hanemann, C. Oliver

AU - Hennigan, Robert

AU - Huson, Susan

AU - Ingram, David

AU - Kissil, Joe

AU - Korf, Bruce R.

AU - Legius, Eric

AU - Packer, Roger J.

AU - Mcclatchey, Andrea I.

AU - Mccormick, Frank

AU - North, Kathryn

AU - Pehrsson, Minja

AU - Plotkin, Scott R.

AU - Ramesh, Vijaya

AU - Ratner, Nancy

AU - Schirmer, Susann

AU - Sherman, Larry

AU - Schorry, Elizabeth

AU - Stevenson, David

AU - Stewart, Douglas R.

AU - Ullrich, Nicole

AU - Bakker, Annette C.

AU - Morrison, Helen

PY - 2014/3

Y1 - 2014/3

N2 - The neurofibromatoses (NF) are autosomal dominant genetic disorders that encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect more people worldwide than Duchenne muscular dystrophy and Huntington's disease combined. NF1 and NF2 are caused by mutations of known tumor suppressor genes (NF1 and NF2, respectively). For schwannomatosis, although mutations in SMARCB1 were identified in a subpopulation of schwannomatosis patients, additional causative gene mutations are still to be discovered. Individuals with NF1 may demonstrate manifestations in multiple organ systems, including tumors of the nervous system, learning disabilities, and physical disfigurement. NF2 ultimately can cause deafness, cranial nerve deficits, and additional severe morbidities caused by tumors of the nervous system. Unmanageable pain is a key finding in patients with schwannomatosis. Although today there is no marketed treatment for NF-related tumors, a significant number of clinical trials have become available. In addition, significant preclinical efforts have led to a more rational selection of potential drug candidates for NF trials. An important element in fueling this progress is the sharing of knowledge. For over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share novel findings, ideas, and build collaborations. The 2012 NF Conference held in New Orleans hosted over 350 NF researchers and clinicians. This article provides a synthesis of the highlights presented at the conference and as such, is a "state-of-the-field" for NF research in 2012.

AB - The neurofibromatoses (NF) are autosomal dominant genetic disorders that encompass the rare diseases NF1, NF2, and schwannomatosis. The NFs affect more people worldwide than Duchenne muscular dystrophy and Huntington's disease combined. NF1 and NF2 are caused by mutations of known tumor suppressor genes (NF1 and NF2, respectively). For schwannomatosis, although mutations in SMARCB1 were identified in a subpopulation of schwannomatosis patients, additional causative gene mutations are still to be discovered. Individuals with NF1 may demonstrate manifestations in multiple organ systems, including tumors of the nervous system, learning disabilities, and physical disfigurement. NF2 ultimately can cause deafness, cranial nerve deficits, and additional severe morbidities caused by tumors of the nervous system. Unmanageable pain is a key finding in patients with schwannomatosis. Although today there is no marketed treatment for NF-related tumors, a significant number of clinical trials have become available. In addition, significant preclinical efforts have led to a more rational selection of potential drug candidates for NF trials. An important element in fueling this progress is the sharing of knowledge. For over 20 years the Children's Tumor Foundation has convened an annual NF Conference, bringing together NF professionals to share novel findings, ideas, and build collaborations. The 2012 NF Conference held in New Orleans hosted over 350 NF researchers and clinicians. This article provides a synthesis of the highlights presented at the conference and as such, is a "state-of-the-field" for NF research in 2012.

KW - Merlin neurofibromin

KW - Neurofibromatosis type 1

KW - Neurofibromatosis type 2

KW - NF1

KW - NF2

KW - Preclinical models

KW - Schwannomatosis

KW - SMARCB1

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=84894241229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894241229&partnerID=8YFLogxK

U2 - 10.1002/ajmg.a.36312

DO - 10.1002/ajmg.a.36312

M3 - Article

C2 - 24443315

AN - SCOPUS:84894241229

VL - 164

SP - 563

EP - 578

JO - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

JF - American Journal of Medical Genetics, Part C: Seminars in Medical Genetics

SN - 1552-4825

IS - 3

ER -